{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-003449","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2022-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.111598+00:00","generated_at":"2026-06-27T12:39:58.465985+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"IDEXX Q4 revenue $801M (+11%), full-year EPS $8.60 (+28%); guides 2022 revenue $3.5-$3.565B","bullets":["Q4 revenue $801M, up 11% reported and 10.5% organic; CAG Diagnostics recurring revenue grew 13%.","Full-year EPS $8.60, up 28% reported and 29% comparable; operating margin expanded 330 bps reported.","Record premium instrument placements drove 14% YoY expansion of global installed base.","Initial 2022 guidance: revenue $3,500M-$3,565M (9-11% growth), EPS $9.27-$9.59 (8-11% growth).","U.S. same-store clinical visit growth 2% in Q4; on a two-year basis, visits up 5.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-003449","json":"https://secwatch.observer/filing/0001564590-22-003449.json","markdown":"https://secwatch.observer/filing/0001564590-22-003449.md","text":"https://secwatch.observer/filing/0001564590-22-003449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000156459022003449/0001564590-22-003449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000156459022003449/idxx-8k_20220202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T12:39:58.465985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}